This year in Australia, over 15,000 women and 150 men will be diagnosed with breast cancer and around 3,000 will die from the disease. It is the most common cancer diagnosed in women, who have a 1 in 8 chance of getting breast cancer by the age of 85.
This is why investing in breast cancer research is so important. Over the last 5 years, Cancer Council NSW has funded $6.1 million into breast cancer research.
Research we are currently funding:
This project will lay the foundations for possible clinical trials of drugs targeting the ELF5 protein as a way of preventing hormone therapy resistance in breast cancer.
If the project is successful, it would be one of the first targeted treatments for triple-negative breast cancer, with potential for improved survival rates.
This project is a critical step to expand treatment options and could also pave the way for development of immune therapies for breast cancer.
This project will provide the critical clinical evidence on the effectiveness of adding progesterone to antiestrogenic therapies in patients with early stage breast cancer.
This research builds on previous findings that the protein MCL-1 acts like a life and death switch for triple negative breast cancer cells.
This study will explore whether certain microRNAS could be targeted in combination with chemotherapy to kill breast cancer cells and improve patient outcomes.
Professor Clark is testing the use of a new molecular target, which is able to predict whether a patient will respond to therapy.
Chemotherapy is the most common treatment for triple negative breast cancer, but the disease often comes back. Prof Baxter's team is studying possible new drug combinations.
Professor Clarke's team is unravelling the complexities of breast cancer by providing new insight into the structure of the normal breast and how progesterone may be linked with cancer risk.
Dr Verrills’ project focuses on identifying the mechanisms that drive Luminal B breast cancer, generating new diagnostic tests and therapies that can target this type of cancer.
Resistance to endocrine therapies is common, affecting around 40% of people who undergo treatment for breast cancer.
Impact we've achieved with our research:
This project has worked to improve treatments and reduce the major challenge of some breast cancer patients’ resistance to endocrine therapy and relapse.
Professor Robert Baxter and his team have tested a promising new therapy, which can effectively block the growth of triple negative breast cancer by inhibiting two proteins that act as stimu
Shirley Baxter talks about representing consumers in deciding what research Cancer Council funds.
A team of researchers led by Dr Nicole Verrills has been investigating if a new ‘gene marker’ can predict which breast cancer patients may have poorer treatment outcomes.
Professor Bettina Meiser is leading a world-first study on the impacts of testing women for common, low-risk genetic variants that can lead to breast cancer.